Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sutro Biopharma (STRO) Interest Expenses (2017 - 2022)

Sutro Biopharma's Interest Expenses history spans 6 years, with the latest figure at $2.8 million for Q3 2022.

  • For Q3 2022, Interest Expenses rose 240.0% year-over-year to $2.8 million; the TTM value through Jun 2023 reached $2.8 million, up 3.91%, while the annual FY2021 figure was $3.1 million, 23.06% down from the prior year.
  • Interest Expenses for Q3 2022 was $2.8 million at Sutro Biopharma, up from $594000.0 in the prior quarter.
  • Across five years, Interest Expenses topped out at $3.0 million in Q2 2020 and bottomed at -$2.3 million in Q4 2020.
  • The 5-year median for Interest Expenses is $820000.0 (2021), against an average of $805947.4.
  • The largest annual shift saw Interest Expenses surged 343.0% in 2019 before it plummeted 375.52% in 2020.
  • A 5-year view of Interest Expenses shows it stood at -$649000.0 in 2018, then surged by 225.89% to $817000.0 in 2019, then plummeted by 375.52% to -$2.3 million in 2020, then soared by 127.19% to $612000.0 in 2021, then soared by 355.56% to $2.8 million in 2022.
  • Per Business Quant, the three most recent readings for STRO's Interest Expenses are $2.8 million (Q3 2022), $594000.0 (Q2 2022), and $657000.0 (Q1 2022).